Detailed Quote for Cannabis Science Inc. (CBIS) $ 0,052 0,0143 (+37.93%) Volume: 16,65 m 15:59 EDT 20.09.2012
Ich bin mir sicher , das Cannabis Science endlich den Weg des konstanten Erfolges einschlägt (wovon ich fest überzeugt bin)und eröffne hiermit einen neuen Thread, der den User als Plattform für Gedankenaustausch dienen soll .
Hammer News von gestern :
September 20, 2012 - 1:45 PM EDT
NBC News Reports that Cannabidiol (CBD) "Turns Off" the Cancer Gene Involved in Metastasis Findings by Scientists at California Pacific Medical Center gives Scientific Support for Cannabis Science Initiatives
Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, reports on a recent press release by the San Francisco NBC news, with new studies by Scientists at California Pacific Medical Center, which have shown that cannabidiol, (CBD), has the ability to "turn off" a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.
NBC News reports, "The drug "has been shown to reduce pain and nausea" in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. "What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they've found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers."
Cannabis Science appreciates this additional scientific support that this report provides for our two target drug development programs as the Company moves forward with CS-TATI-1, and based on the success of previous skin cancer patients who self-administered cannabis-based treatments, the Company is focusing on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Dr. Robert Melamede states, "Cannabis Science is excited for the increasing scientific support for our projects. In the near future, we will share new developments, as well a the progress we have made with our earlier defined initiatives. Our professional expansion and development, as detailed in our latest news releases,was driven by the science of how cannabinoids can benefit both HIV/AIDS and Cancer Patients."
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Cannabis Science has already seen success with 4 self-medicated skin cancer patients. These patients have been self-administering using cannabis-based extracts applied topically to their carcinomas and tumors. These patients have experienced shrinking and apparent eradication of their skin cancer, backed by positive reports from their doctors, which is why the Company is confident about the eminent success of this new drug to be developed.
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science"s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1"s, PO1"s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for several critical ailments. The Company is currently developing two formulation drugs for critical ailments, Skin Cancer and HIV/AIDS. The Company works with leading experts in new drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Preclinical development of CS-TATI-1 appears to inhibit HIV associated Kaposi Sarcoma by inhibiting HIV Tat. This cancer is significant threat to people with HIV. HIV Tat protein appears to trans activate Kaposi sarcoma. The inhibition of HIV Tat offers a promising new approach to inhibiting KSHV infective cycle.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company"s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Source: Business Wire (September 20, 2012 - 1:45 PM EDT)
CANNABIS SCIENCE TO FILE OFFERING MEMORANDUM FOR 25 MILLION USD IN EXPANSION CAPITAL IRVINE, CA--(Marketwired - Apr 7, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it will file a 25 million USD offering memorandum to accommodate an aggressive expansion plan; the Company expects to file next week. The Company has been reviewing investment firms that have expressed interest in its business model and similar humanitarian interests. With this new growth plan the Company is now looking for a corporate office in NYC to facilitate its financing initiatives and its east coast expansion plans.
The Company has received a considerable increase in activity from its recent collaboration research agreement with Dana-Farber to research cannabis-based cancer treatments and multiple leadership speaking engagements at Harvard Medical School. The anticipated 25 Million in new funding will allow Cannabis Science to jump-start its aggressive Drug Development programs with its extensive cannabinoid formulation base targeting multiple critical ailments.
"As regulation changes swiftly in such an enormous expanding industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. Our expansion program is being fueled by the growing market and demand. These investments are for individuals or corporations interested in participating in the CBIS property development projects and fund the future costs of FDA approval's process and Drug and Developments costs for its related targets. This all adds additional strength to this ever changing and growing Cannabis industry and we are all very proud to be right in the middle of it all," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 SEC Accession No. 0001562884-17-000018 Filing Date 2017-03-31 Accepted 2017-03-31 07:18:47 Documents 1 Period of Report 2016-12-31 Filing Date Changed 2017-03-31 Effectiveness Date 2017-03-31